Manning & Napier Life Sciences
290 Woodcliff Drive Fairport, NY 14450
Map
Phone: 800-466-3863
| Category: | Health | | Fund Family: | Manning & Napier | | Net Assets: | 254.56M | | Year-to-Date Return: | 40.77% | | Yield: | 0.00% | | Morningstar Rating: |  | | Fund Inception Date: | 05-Nov-99 |
|
Jeffrey S. Coons
Lead Manager since
05-Nov-99 | | | Coons is a senior analyst. He joined Manning & Napier Advisors in 1993. Coons has been a senior analyst and co-director of research since 2002. He has been a member of the Senior Research Group since 1993, and a member of the Executive Group since 1999. He holds the Charted Financial Analyst designation. |
| Min Initial Investment: | $2,000 | | Min Initial Investment, IRA: | $0 | | Min Initial Investment, AIP: | $2,000 | | Min Subsequent Investment: | $0 | | Min Subsequent Investment, IRA: | $0 | | Min Subsequent Investment, AIP: | $25 |
|
| |
| The investment seeks long-term growth. The fund invests at least 80% of assets in securities of companies involved in the life sciences industry. It may invest in U.S. and foreign stocks, including American Depository Receipts (ADRs) and other U.S. dollar denominated securities of foreign issuers. The fund is nondiversified. |
| Last Dividend
(16-Sep-02):
| 0.00 | | Last Cap Gain
(15-Sep-08):
| 0.11 | | Annual Holdings Turnover
| 94.00% | | Average for Category:
| 109.30% |
|
| Expense | EXLSX | Category
Avg | | Total Expense Ratio: | 1.12%
| 1.67% | | Max 12b1 Fee: | %
| N/A | | Max Front End Sales Load: | %
| 5.35% | | Max Deferred Sales Load: | %
| 2.88% | | 3 Yr Expense Projection*: |
$ 356 | $716 | | 5 Yr Expense Projection*: |
$ 617 | $1,069 | | 10 Yr Expense Projection*: |
$ 1,363 | $2,090 |
|
|
2.03% Nasdaq 
Profile
